Health Rounds: Once-weekly insulin from Eli Lilly appears effective as daily injectionsReuters • 09/11/24
Forget Mounjaro: 1 Reason Investors Should Love Eli Lilly Stock Even More (Hint: I'm Not Talking About Zepbound)The Motley Fool • 09/11/24
With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetesPRNewsWire • 09/10/24
Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetesPRNewsWire • 09/10/24
The Highly Anticipated FDA Approvals of Galderma's Nemolizumab and Eli Lilly's Lebrikizumab are Expected to Shift Dermatologists' Perceptions of the Atopic Dermatitis MarketGlobeNewsWire • 09/09/24
Lilly appoints Lucas Montarce as executive vice president and chief financial officerPRNewsWire • 09/09/24
This Unstoppable Stock Has Gained 100,203% Over The Last 50 Years, Creating Many Millionaires in the Process. Here Are 3 Reasons I Think It Will Continue to Create Generational Wealth.The Motley Fool • 09/08/24
Beyond Mounjaro and Zepbound: 6 Other Drugs That Could Be Blockbusters for Eli LillyThe Motley Fool • 09/08/24
Health Rounds: Next generation Lilly weight-loss drug shows added heart, liver benefitsReuters • 09/06/24
This Big Move by Eli Lilly May Solve the Weight Loss Drug Market's Biggest ProblemThe Motley Fool • 09/06/24
Eli Lilly and Company (LLY) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/05/24
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.The Motley Fool • 09/05/24
In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulinPRNewsWire • 09/05/24
How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, AppleInvestors Business Daily • 09/04/24